Skip to main content
Top
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients

Authors: Zhiyong Liang, Xuan Zeng, Jie Gao, Shafei Wu, Peng Wang, Xiaohua Shi, Jing Zhang, Tonghua Liu

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

The EGFR and HER2 genes are located on chromosomes 7 and 17, respectively. They are therapeutic targets in some tumors. The TOP2A gene, which is located near HER2 on chromosome 17, is the target of many chemotherapeutic agents, and co-amplification of HER2 and TOP2A has been described in several tumor types. Herein, we investigated the gene status of EGFR, HER2, and TOP2A in Chinese gastric carcinoma patients. We determined the rate of polysomy for chromosomes 7 and 17, and we attempted to clarify the relationship between EGFR, HER2, and TOP2A gene copy number and increased expression of their encoded proteins. Furthermore, we tried to address the relationship between alterations in EGFR, HER2, and TOP2A and chromosome polysomy.

Methods

One hundred cases of formalin fixed and paraffin embedded tumor tissues from Chinese gastric carcinoma patients were investigated by immunohistochemistry and fluorescence in situ hybridization (FISH) methods.

Results

Forty-two percent of the cases showed EGFR overexpression; 16% showed EGFR FISH positive; 6% showed HER2 overexpression; and 11% showed HER2 gene amplification, including all six HER2 overexpression cases. TOP2A nuclear staining (nuclear index, NI) was determined in all 100 tumors: NI values ranged from 0.5 – 90%. Three percent of the tumors showed TOP2A gene amplification, which were all accompanied by HER2 gene amplification. Nineteen percent of the tumors showed chromosome 7 polysomy, and 16% showed chromosome 17 polysomy. Chromosome 7 polysomy correlated significantly with EGFR FISH-positivity, but was not associated with EGFR overexpression. HER2 overexpression associated significantly with HER2 gene amplification. TOP2A gene amplification was significantly associated with HER2 gene amplification. No relationship was found between alterations in the EGFR, HER2, and TOP2A genes and clinicopathologic variables of gastric carcinoma.

Conclusion

The data from our study suggest that chromosome 7 polysomy may be responsible for increased EGFR gene copy number in gastric carcinomas, and that HER2 gene amplification may be the major reason for HER2 protein overexpression. A combined investigation of the gene status of EGFR, HER2, and TOP2A should facilitate the identification of a target therapeutic regimen for gastric carcinoma patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Corley DA, Buffler PA: Oesophageal and gastric cardia adenocarcinoma: analysis of regional variation using the Cancer Incidence in FIVE Contiinents database. Int J Epidemiol. 2001, 30: 1415-25. 10.1093/ije/30.6.1415.CrossRefPubMed Corley DA, Buffler PA: Oesophageal and gastric cardia adenocarcinoma: analysis of regional variation using the Cancer Incidence in FIVE Contiinents database. Int J Epidemiol. 2001, 30: 1415-25. 10.1093/ije/30.6.1415.CrossRefPubMed
2.
go back to reference Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y, Fujino MA, Ooi A: Status of c-ERBB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer. 2002, 98: 833-837. 10.1002/ijc.10257.CrossRefPubMed Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y, Fujino MA, Ooi A: Status of c-ERBB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer. 2002, 98: 833-837. 10.1002/ijc.10257.CrossRefPubMed
3.
go back to reference García I, Vizoso F, Martín A, Sanz L, Abdel-Lah O, Raigoso P, García-Muñiz JL: Clinical significance of the epidermal growth factor receptor and HER2 receptor in respectable gastric cancer. Ann Surg Oncol. 2003, 10: 234-241. 10.1245/ASO.2003.05.010.CrossRefPubMed García I, Vizoso F, Martín A, Sanz L, Abdel-Lah O, Raigoso P, García-Muñiz JL: Clinical significance of the epidermal growth factor receptor and HER2 receptor in respectable gastric cancer. Ann Surg Oncol. 2003, 10: 234-241. 10.1245/ASO.2003.05.010.CrossRefPubMed
4.
go back to reference Costa MJ, Walls J: Epidermal growth factor receptor and c-erbB-2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed mullerian tumors). Clinicopathologic study of 82 cases. Cancer. 1996, 77: 533-542. 10.1002/(SICI)1097-0142(19960201)77:3<533::AID-CNCR16>3.0.CO;2-5.CrossRefPubMed Costa MJ, Walls J: Epidermal growth factor receptor and c-erbB-2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed mullerian tumors). Clinicopathologic study of 82 cases. Cancer. 1996, 77: 533-542. 10.1002/(SICI)1097-0142(19960201)77:3<533::AID-CNCR16>3.0.CO;2-5.CrossRefPubMed
5.
go back to reference Wright C, Angus B, Nicholson S, Sainsbury JR, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CH: Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989, 49: 2087-2090.PubMed Wright C, Angus B, Nicholson S, Sainsbury JR, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CH: Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989, 49: 2087-2090.PubMed
6.
go back to reference Soh J, Toyooka S, Ichihara S, Fujiwara Y, Hotta K, Suehisa H, Kobayashi N, Ichimura K, Aoe K, Aoe M, Kiura K, Date H: Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer. Int J Cancer. 2007, 121: 1162-7. 10.1002/ijc.22818.CrossRefPubMed Soh J, Toyooka S, Ichihara S, Fujiwara Y, Hotta K, Suehisa H, Kobayashi N, Ichimura K, Aoe K, Aoe M, Kiura K, Date H: Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer. Int J Cancer. 2007, 121: 1162-7. 10.1002/ijc.22818.CrossRefPubMed
7.
go back to reference Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL: Epidermal growth factor receptor (HER1) tyrosine kinase inhibithor ZD1839(Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 2001, 61: 8887-8895.PubMed Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL: Epidermal growth factor receptor (HER1) tyrosine kinase inhibithor ZD1839(Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 2001, 61: 8887-8895.PubMed
8.
go back to reference Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 2002, 21: 6255-6263. 10.1038/sj.onc.1205794.CrossRefPubMed Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 2002, 21: 6255-6263. 10.1038/sj.onc.1205794.CrossRefPubMed
9.
go back to reference Järvinen TAH, Liu ET: Simultaneous amplification of HER-2(ERBB2) and Topoisomerase IIα (TOP2A) genes-molecular basis for combination chemotherapy in cancer. Current Cancer Drug Targets. 2006, 6: 579-602. 10.2174/156800906778742497.CrossRefPubMed Järvinen TAH, Liu ET: Simultaneous amplification of HER-2(ERBB2) and Topoisomerase IIα (TOP2A) genes-molecular basis for combination chemotherapy in cancer. Current Cancer Drug Targets. 2006, 6: 579-602. 10.2174/156800906778742497.CrossRefPubMed
10.
go back to reference Mano MS, Rosa DD, Azambuja ED, Ismael GFV, Durdecq V: The 17q12-q21 amplicon:Her2 and topoisomerase – IIα and their importance to the biology of solid tumors. Cancer Treatment Reviews. 2007, 33: 64-77. 10.1016/j.ctrv.2006.10.001.CrossRefPubMed Mano MS, Rosa DD, Azambuja ED, Ismael GFV, Durdecq V: The 17q12-q21 amplicon:Her2 and topoisomerase – IIα and their importance to the biology of solid tumors. Cancer Treatment Reviews. 2007, 33: 64-77. 10.1016/j.ctrv.2006.10.001.CrossRefPubMed
11.
go back to reference Buckingham LE, Coon JS, Morrison LE, Jacobson KK, Jewell SS, Kaiser KA, Mauer AM, Muzzafar T, Polowy C, Basu S, Gale M, Villaflor VM, Bonomi P: The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. J Thorac Oncol. 2007, 2: 414-22. 10.1097/01.JTO.0000268675.02744.b0.CrossRefPubMed Buckingham LE, Coon JS, Morrison LE, Jacobson KK, Jewell SS, Kaiser KA, Mauer AM, Muzzafar T, Polowy C, Basu S, Gale M, Villaflor VM, Bonomi P: The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. J Thorac Oncol. 2007, 2: 414-22. 10.1097/01.JTO.0000268675.02744.b0.CrossRefPubMed
12.
go back to reference Wang S, Saboorian MH, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, Hynan L, Ashfaq R: Aneusomy 17 in breast cancer: Its role in Her2/neu protein expression and implication for clinical assessment of Her-2/neu status. Mod Pathol. 2002, 15: 137-145. 10.1038/modpathol.3880505.CrossRefPubMed Wang S, Saboorian MH, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, Hynan L, Ashfaq R: Aneusomy 17 in breast cancer: Its role in Her2/neu protein expression and implication for clinical assessment of Her-2/neu status. Mod Pathol. 2002, 15: 137-145. 10.1038/modpathol.3880505.CrossRefPubMed
13.
go back to reference Flemming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, O'Sullivan B, Sobin LH, Yarbro JW, editors: AJCC cancer staging manual. 1997, Philadelphia (Pa)7 Lippincott-Raven, 5 Flemming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, O'Sullivan B, Sobin LH, Yarbro JW, editors: AJCC cancer staging manual. 1997, Philadelphia (Pa)7 Lippincott-Raven, 5
14.
go back to reference Fenoglio-Preiser C: Tumours of the stomach. WHO classification of tumours. Edited by: Hamilton S, Aaltonen LA. 2000, Lyon7 IARC Press Fenoglio-Preiser C: Tumours of the stomach. WHO classification of tumours. Edited by: Hamilton S, Aaltonen LA. 2000, Lyon7 IARC Press
15.
go back to reference Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, Vijver van de M, Wheeler TM, Hayes DF, American Society of Clinical Oncology; College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 25: 118-145. 10.1200/JCO.2006.09.2775. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, Vijver van de M, Wheeler TM, Hayes DF, American Society of Clinical Oncology; College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 25: 118-145. 10.1200/JCO.2006.09.2775.
16.
go back to reference Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA, Varella-Garcia M: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005, 97: 643-55.CrossRefPubMed Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA, Varella-Garcia M: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005, 97: 643-55.CrossRefPubMed
17.
go back to reference Shin HJ, Shin DM, Tarco E, Sneige N: Detection of Numerical Aberrations of Chromosomes 7 and 9 in Cytologic Specimens of Pleural Malignant mesothelioma. Cancer. 2003, 99 (4): 233-239. 10.1002/cncr.11398.CrossRefPubMed Shin HJ, Shin DM, Tarco E, Sneige N: Detection of Numerical Aberrations of Chromosomes 7 and 9 in Cytologic Specimens of Pleural Malignant mesothelioma. Cancer. 2003, 99 (4): 233-239. 10.1002/cncr.11398.CrossRefPubMed
18.
go back to reference Kapranos N, Kounelis S, Karantasis H, Kouri E: Numerical Aberrations of Chromosomes 1 and 7 by Fluorescent in Situ Hybridization and DNA Ploidy Analysis in Breast Cancer. The Breast Journal. 2005, 11: 448-453. 10.1111/j.1075-122X.2005.00123.x.CrossRefPubMed Kapranos N, Kounelis S, Karantasis H, Kouri E: Numerical Aberrations of Chromosomes 1 and 7 by Fluorescent in Situ Hybridization and DNA Ploidy Analysis in Breast Cancer. The Breast Journal. 2005, 11: 448-453. 10.1111/j.1075-122X.2005.00123.x.CrossRefPubMed
19.
go back to reference Kanta SY, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A: Topoisomerase IIα gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Human Pathology. 2006, 37: 1333-1343. 10.1016/j.humpath.2006.05.008.CrossRefPubMed Kanta SY, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A: Topoisomerase IIα gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Human Pathology. 2006, 37: 1333-1343. 10.1016/j.humpath.2006.05.008.CrossRefPubMed
20.
go back to reference Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, Son BH, Cho EY, Chae SW, Kim EJ, Sohn JH, Ryu SH, Sepulveda AR: HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006, 51: 1371-1379. 10.1007/s10620-005-9057-1.CrossRefPubMed Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, Son BH, Cho EY, Chae SW, Kim EJ, Sohn JH, Ryu SH, Sepulveda AR: HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006, 51: 1371-1379. 10.1007/s10620-005-9057-1.CrossRefPubMed
21.
go back to reference Varis A, Zaika A, Puolakkainen P, Nagy B, Madrigal I, Kollola A, Väyrynen A, Kärkkäinen P, Moskaluk C, El-Rifai W, Knuutila S: Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int J Cancer. 2004, 109 (4): 548-553. 10.1002/ijc.20001.CrossRefPubMed Varis A, Zaika A, Puolakkainen P, Nagy B, Madrigal I, Kollola A, Väyrynen A, Kärkkäinen P, Moskaluk C, El-Rifai W, Knuutila S: Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int J Cancer. 2004, 109 (4): 548-553. 10.1002/ijc.20001.CrossRefPubMed
22.
go back to reference Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, Pinto M, Zamboli A, De Vita F, Ferraraccio F: Epidermal Growth Factor Receptor (EGFR) Expression is Associated With a Worse Prognosis in Gastric Cancer Patients Undergoing Curative Surgery. World J Surg. 2007, 31: 1458-1468. 10.1007/s00268-007-9016-4.CrossRefPubMed Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, Pinto M, Zamboli A, De Vita F, Ferraraccio F: Epidermal Growth Factor Receptor (EGFR) Expression is Associated With a Worse Prognosis in Gastric Cancer Patients Undergoing Curative Surgery. World J Surg. 2007, 31: 1458-1468. 10.1007/s00268-007-9016-4.CrossRefPubMed
23.
go back to reference Jeona YK, Sungb SW, Chunga JH, Parke WS, Seoa JW, Kima CW, Chung DH: Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer. 2006, 54: 387-398. 10.1016/j.lungcan.2006.08.015.CrossRef Jeona YK, Sungb SW, Chunga JH, Parke WS, Seoa JW, Kima CW, Chung DH: Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer. 2006, 54: 387-398. 10.1016/j.lungcan.2006.08.015.CrossRef
24.
go back to reference Suzuki S, Dobashi Y, Sakurai H, Nishikawa K, Hanawa M, Ooi A: Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas:an immunohistochemical and fluorescence in situ hybridization study. Cancer. 2005, 103: 1265-73. 10.1002/cncr.20909.CrossRefPubMed Suzuki S, Dobashi Y, Sakurai H, Nishikawa K, Hanawa M, Ooi A: Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas:an immunohistochemical and fluorescence in situ hybridization study. Cancer. 2005, 103: 1265-73. 10.1002/cncr.20909.CrossRefPubMed
25.
go back to reference Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O'Reilly MS, Hong WK, Fidler IJ, Putnam JB, Herbst RS: Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res. 2004, 10 (1 Pt 1): 136-43. 10.1158/1078-0432.CCR-0373-3.CrossRefPubMed Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O'Reilly MS, Hong WK, Fidler IJ, Putnam JB, Herbst RS: Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res. 2004, 10 (1 Pt 1): 136-43. 10.1158/1078-0432.CCR-0373-3.CrossRefPubMed
26.
go back to reference Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremnes RM, Barón AE, Zeng C, Franklin WA: Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003, 21: 3798-807. 10.1200/JCO.2003.11.069.CrossRefPubMed Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremnes RM, Barón AE, Zeng C, Franklin WA: Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003, 21: 3798-807. 10.1200/JCO.2003.11.069.CrossRefPubMed
27.
go back to reference Li TK, Liu LF: Tumor cell death induced by topoisomerase-target drugs. Annu Rev Pharmacol Toxicol. 2001, 41: 53-77. 10.1146/annurev.pharmtox.41.1.53.CrossRefPubMed Li TK, Liu LF: Tumor cell death induced by topoisomerase-target drugs. Annu Rev Pharmacol Toxicol. 2001, 41: 53-77. 10.1146/annurev.pharmtox.41.1.53.CrossRefPubMed
28.
go back to reference Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK, Rosenfeld MG: A topoisomereaseIIβ-mediated dsDNA break required for regulated transcription. Science. 2006, 312: 1798-1802. 10.1126/science.1127196.CrossRefPubMed Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK, Rosenfeld MG: A topoisomereaseIIβ-mediated dsDNA break required for regulated transcription. Science. 2006, 312: 1798-1802. 10.1126/science.1127196.CrossRefPubMed
29.
go back to reference Järvinen TAH, Tanner M, Rantanen V, Bärlund M, Borg A, Grenman S: Amplification and deletion of topoisomerase IIαgene are common in ErbB-2 amplified breast cancer and alter the sensitivity to doxorubicin. Am J Pathol. 2000, 156: 839-847.CrossRefPubMedPubMedCentral Järvinen TAH, Tanner M, Rantanen V, Bärlund M, Borg A, Grenman S: Amplification and deletion of topoisomerase IIαgene are common in ErbB-2 amplified breast cancer and alter the sensitivity to doxorubicin. Am J Pathol. 2000, 156: 839-847.CrossRefPubMedPubMedCentral
30.
go back to reference Varis A, Wolf M, Monni O, Vakkari ML, Kokkola A, Moskaluk C, Frierson H, Powell SM, Knuutila S, Kallioniemi A, El-Rifai W: Targets of gene amplification and overexpression at 17q in gastric cancer. Cancer Res. 2002, 62: 2625-2629.PubMed Varis A, Wolf M, Monni O, Vakkari ML, Kokkola A, Moskaluk C, Frierson H, Powell SM, Knuutila S, Kallioniemi A, El-Rifai W: Targets of gene amplification and overexpression at 17q in gastric cancer. Cancer Res. 2002, 62: 2625-2629.PubMed
31.
go back to reference Simon R, Atefy R, Wagner U, Forster T, Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T, Sauter G: HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer. 2003, 107: 764-772. 10.1002/ijc.11477.CrossRefPubMed Simon R, Atefy R, Wagner U, Forster T, Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T, Sauter G: HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer. 2003, 107: 764-772. 10.1002/ijc.11477.CrossRefPubMed
32.
go back to reference Guerin E, Entz-Werle N, Eyer D, Pencreac'h E, Schneider A, Falkenrodt A, Uettwiller F, Babin A, Voegeli AC, Lessard M, Gaub MP, Lutz P, Oudet P: Modification of topoisomerase genes copy number in newly diagnosed childhood acute lymphoblastic leukemia. Leukemia. 2003, 17: 532-540. 10.1038/sj.leu.2402774.CrossRefPubMed Guerin E, Entz-Werle N, Eyer D, Pencreac'h E, Schneider A, Falkenrodt A, Uettwiller F, Babin A, Voegeli AC, Lessard M, Gaub MP, Lutz P, Oudet P: Modification of topoisomerase genes copy number in newly diagnosed childhood acute lymphoblastic leukemia. Leukemia. 2003, 17: 532-540. 10.1038/sj.leu.2402774.CrossRefPubMed
Metadata
Title
Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients
Authors
Zhiyong Liang
Xuan Zeng
Jie Gao
Shafei Wu
Peng Wang
Xiaohua Shi
Jing Zhang
Tonghua Liu
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-363

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine